Leucovorin (Folinic Acid)

Folinic acid is a reduced form of folate that bypasses the dihydrofolate reductase step, allowing direct conversion to tetrahydrofolate derivatives. This restores folate‑dependent nucleotide synthesis and DNA replication in normal cells, counteracting the blockade caused by antifolate drugs and supporting cellular growth.

The appropriate dose of Leucovorin is determined by the prescribing clinician based on the specific indication, the patient’s renal and hepatic function, the concurrent chemotherapy regimen, and individual therapeutic response. Dosage is individualized and should follow the prescriber’s order.

Safety data for Leucovorin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Leucovorin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Leucovorin (folinic acid) is a reduced folate that directly bypasses dihydrofolate reductase inhibition, offering rapid restoration of folate pathways. Compared with other rescue agents such as calcium folinate, it provides similar efficacy but may differ in formulation and stability, making it suitable for both intravenous and intramuscular administration.

Leucovorin should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking the solution. Follow any additional handling instructions provided by the manufacturer.

Leucovorin is administered by intramuscular or intravenous injection, as directed by the prescribing clinician. The route, rate of infusion, and timing relative to other chemotherapy agents are determined by the treatment protocol and patient-specific factors.

Serious risks, though uncommon, include anaphylactic reactions, severe hypotension, acute renal or hepatic dysfunction, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these events, especially during the initial administration.

Leucovorin is contraindicated in patients with known hypersensitivity to folinic acid or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in situations where it could diminish the intended effect of concurrent antifolate chemotherapy.